Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of AR096626A1publicationCriticalpatent/AR096626A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La solicitud proporciona conjugados anticuerpo-fármaco que comprenden un anticuerpo conjugado a un resto de fármaco dimérico de 1-(clorometil)-2,3-dihidro-1H-benzo[e]indol (CBI) mediante un ligante, y método para utilizar los conjugados anticuerpo-fármaco.The application provides antibody-drug conjugates comprising an antibody conjugated to a dimeric drug moiety of 1- (chloromethyl) -2,3-dihydro-1H-benzo [e] indole (CBI) by a binder, and method of using the antibody-drug conjugates.
ARP140102283A2013-08-122014-06-16
ANTIBODY-DRUG CONJUGATE COMPOUNDS 1- (CHLOROME) -2,3-DIHIDRO-1H-BENZO [E] INDOL, AND METHODS OF USE AND TREATMENT
AR096626A1
(en)
binder-drug intermediate, antibody-drug conjugate compounds, pharmaceutical compositions, methods for treating cancer, method of producing an antibody-drug conjugate and conjugate
amatoxine conjugate and its use, pharmaceutical composition and its use, amatoxine conjugation molecule, method for the synthesis of an amatoxine conjugate.
Pharmaceutical dosage form comprising 6-fluoro - (n-methyl-or n, n-dimethyl) -4-phenyl -4,9-dihydro-3h-spiro - (cyclohexan-1,1-pyran (3,4, b) indole) -4-amine, useful as an analgesic